

RELATIONSHIPS WITH INDUSTRY (RWI) AND OTHER ENTITIES

The ACC and its partnering organizations rigorously avoid any actual, perceived, or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the rating panel. Specifically, all panelists are asked to provide disclosure statements of all relationships that might be perceived as real or potential conflicts of interest. These statements were reviewed by the Appropriate Use Criteria Task Force, discussed with all members of the rating panel at the face-to-face meeting, and updated and reviewed as necessary. The following is a full list of disclosures by all participants, including relationships not pertinent to this document.

Appropriate Use Criteria for Peripheral Artery Intervention: Members of the Writing Group, Rating Panel, External Reviewers, and AUC Task Force—Relationships with Industry and Other Entities (Comprehensive)

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Writing Group								
Steven R. Bailey, MD, <i>Chair</i>	University of Texas Health Science Center at San Antonio— Program Director, Interventional Cardiology; Professor of Medicine and Radiology	ACC	None	None	None	• Boston Scientific (DSMB)	• Edwards*	None
Joshua A. Beckman, MD	Vanderbilt University Medical Center, Cardiovascular Fellowship Program— Director	ACC	• Aralez† • AstraZeneca† • Janssen Pharmaceuticals • Merck† • Sanofi	None	• EMX‡ • JanaCare‡	• Bayer (DSMB)† • Bristol Myers Squibb†	• Vascular Interventional Advances (Officer)†	• Defendant, venous thromboembolism, 2015†
Timothy D. Dao, MD	Heart Place Plano— Staff Cardiologist	ACC	None	None	None	None	None	None

2018 Appropriate Use Criteria for Peripheral Artery Intervention
CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Sanjay Misra, MD	Mayo Clinic, Division of Vascular and Interventional Radiology—Professor of Radiology	SIR	None	None	None	• Flextend (DSMB)	• National Institutes of Health†	None
Piotr S. Sobieszczyk, MD	Brigham and Women's Hospital and Harvard Medical School, Vascular Medicine Section, Cardiac Catheterization Lab—Associate Director	SVM	None	None	None	None	• Edwards* • ReCor Medical*	• Defendant, IVC filter embolization, 2014‡
Christopher J. White, MD	Ochsner Medical Center—Chief of Medical Services; The Ochsner Clinical School, University of Queensland—Professor and Chairman of Medicine	SCAI	• Neovasc	None	None	• Astra Zeneca Pharmaceuticals • Crest-2 Trial	• ACE Board of Directors‡ • National Institutes of Health (Executive Committee, and Crest 2 Interventional Management Committee) • Neovasc (Scientific Advisory Board) • Surmodics (Scientific Advisory Board)	None
Rating Panel								

2018 Appropriate Use Criteria for Peripheral Artery Intervention
CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Herbert D. Aronow, MD	Lifespan Cardiovascular Institute, Interventional Cardiology—Director; Rhode Island and The Miriam Hospitals, Cardiac Catheterization Laboratories— Director; Warren Alpert Medical School of Brown University— Assistant Professor of Medicine	SVM	None	None	None	<ul style="list-style-type: none"> • PCORI (Clinical Expert Panel)‡ • PORTRAIT (Co-PI)‡ 	<ul style="list-style-type: none"> • Abbott Vascular* • Bard* • Gardia Medical* • Gore* • National Institutes of Health* • Silk Road Medical* • Society for Coronary Angiography and Interventions (Officer)‡ • Society for Vascular Medicine (Trustee)‡ 	<ul style="list-style-type: none"> • Plaintiff, peripheral coronary and vascular intervention appropriateness, 2014†
Reza Fazel, MD	Brigham and Women's Hospital, Division of Cardiology— Associate Physician	ACC	None	None	None	None	None	None
Heather L. Gornik, MD	Cleveland Clinic Foundation Cardiovascular Medicine, Vascular Medicine—Section Head; Cleveland Clinic Learner College of Medicine of Case Western Reserve University—Associate Professor of Medicine	ACC	<ul style="list-style-type: none"> • Northwestern University (Advisory Committee) 	None	<ul style="list-style-type: none"> • Summit Doppler Systems‡ • Zin Medical‡ 	<ul style="list-style-type: none"> • AstraZeneca – Euclid Trial (PI)† 	<ul style="list-style-type: none"> • American Heart Association (Officer)‡ • Astra Zeneca* • Fibromuscular Dysplasia Society of America (Officer)‡ • Intersocietal Accreditation Commission - Vascular Testing (Officer) • Society of Vascular Medicine (Officer)‡ 	<ul style="list-style-type: none"> • Defendant, deep vein thrombosis, 2011‡
Bruce H. Gray, D.O.	Greenville Health System, Endovascular Service—Director; University of South Carolina School of Medicine—Professor of Surgery/Vascular Medicine	SVM	None	None	None	<ul style="list-style-type: none"> • Abbott‡ 	<ul style="list-style-type: none"> • Cordis* • Gore* • NCDR Registry Committee (Steering Committee Member) 	None

2018 Appropriate Use Criteria for Peripheral Artery Intervention
CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Jonathan L. Halperin, MD	Mount Sinai Medical Center—Professor of Medicine	ACC	<ul style="list-style-type: none"> • American Board of Internal Medicine† • Bayer Healthcare Pharmaceuticals† • Boehringer Ingelheim† • Medtronic, Inc. • Ortho-McNeil-Janssen • Pfizer, Inc.† 	None	• HWL, LLC‡	• NIH (NHLBI)‡	None	• Defendant, pericardiocentesis, 2016
Alan T. Hirsch, MD	University of Minnesota Medical School—Professor of Medicine, Epidemiology, and Community Health; Vascular Medicine Program—Director	ACC	<ul style="list-style-type: none"> • AstraZeneca Pharmaceuticals • Merck 	None	None	<ul style="list-style-type: none"> • Bayer Healthcare Pharmaceutical† • Pluristem† 	<ul style="list-style-type: none"> • American Heart Association - Council and Educational Committee (Member)‡ • AstraZeneca Pharmaceuticals* • Pluristem* • Tactile Medical (Officer)† 	
Michael R. Jaff, D.O.	Newton-Wellesley Hospital—President; Harvard Medical School—Professor of Medicine	SCAI	<ul style="list-style-type: none"> • AOPA† • Cardinal Health • Micell • Vascular Therapies • Volcano/Philips 	None	<ul style="list-style-type: none"> • Embolitech† • Gemini • Janacare‡ • MC10‡ • Northwind • PQ Bypass • Primacea • Sano V • Vactronix • Valiant Medical • Venarum 	<ul style="list-style-type: none"> • Novello (Chair-DSMB) 	<ul style="list-style-type: none"> • Abbott Vascular (Advisor)‡ • Boston Scientific (Advisor)‡ • CBSET (Board Member)† • Cordis (Advisor)‡ • Intersocietal Accreditation Commission (Officer) • Medtronic Vascular (Advisor)‡ • Society for Cardiovascular Angiography and Interventions (Officer)‡ • VIVA Physicians Group (Officer)† 	None

2018 Appropriate Use Criteria for Peripheral Artery Intervention
CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Venkataramu Krishnamurthy MBBS	VA Ann Arbor Health System—Chief of Radiology Services; University of Michigan Hospitals—Clinical Professor of Radiology and Vascular Surgery	SIR	None	None	None	None	None	None
Sahil A. Parikh, MD	Columbia University Irving Medical Center/ NY Presbyterian Hospital, Center for Interventional Vascular Therapy, Endovascular Services—Director; Columbia University Vagelos College of Physicians and Surgeons—Associate Professor of Medicine	ACC	<ul style="list-style-type: none"> • Abbott Vascular† • Abiomed • Asahi • Boston Scientific† • Heartflow • Medtronic† • Siemens • Spectranetics • St. Jude Medical • Teleflex • Terumo 	<ul style="list-style-type: none"> • Astra Zeneca Pharmaceutical • Lutonix/CR Bard • Spectranetics • St. Jude Medical • Terumo† • The Medicines Company 	None	<ul style="list-style-type: none"> • Abiomed • AstraZeneca Pharmaceutical‡ • Lutonix/CR Bard • Medtronic • Shockwave Medical‡ • Silk Road (DSMB) • TriReme Medical‡ 	<ul style="list-style-type: none"> • Abbott (Advisory Board)‡ • Boston Scientific (Advisory Board)‡ • Cardio Kinetix* • Medtronic (Advisory Board)‡ • Spectranetics (Advisory Board)‡ • TriReme Medical* 	None
Amy B. Reed, MD	Fairview Vascular Services—Director; University of Minnesota, Vascular and Endovascular Surgery—Professor and Chief	SVS	None	None	None	None	None	None
Fadi Shamoun, MD	Mayo Clinic, Anticoagulation Clinic—Medical Director; Division of Cardiovascular Diseases, Vascular Medicine—Assistant Professor of Medicine	ACC	None	None	None	None	None	None
Rita E. Shugart, RN, RVT	Shugart Consulting—Vascular Ultrasound	SVU	None	None	None	None	None	None

2018 Appropriate Use Criteria for Peripheral Artery Intervention
CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
E. Kent Yucel, MD	Tufts Medical Center—Chair and Professor of Radiology	ACR	None	None	None	None	None	None
External Reviewers								
Christopher J. Abularrage, MD	The Johns Hopkins Hospital, Diabetic Foot and Wound Clinic—Director and Associate Professor of Surgery	SVS	• Medtronic	None	None	None	None	None
H. Vernon Anderson, MD	Memorial Hermann Heart and Vascular Institute, McGovern Medical School, and University of Texas Health Science Center—Professor of Medicine and Cardiology	ACC	• Accreditation for Cardiovascular Excellence • American Medical Foundation	None	None	• MedPace Medical Devices (DSMB)	• Capricor*	None
Ehrin J. Armstrong, MD, MSc	VA Eastern Colorado Healthcare System, Interventional Cardiology—Cardiology Director; and Vascular Laboratory—Co-Director; University of Colorado—Associate Professor of Medicine	AHA	• Abbott Vascular • Abiomed • Boston Scientific • Cardiovascular Systems • Medtronic • Spectranetics	None	None	None	None	None
Mark Otto Baerlocher, MD	Royal Victoria Hospital, Interventional Radiology—Chief	SIR	• Boston Scientific	None	None	None	None	None

2018 Appropriate Use Criteria for Peripheral Artery Intervention
CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Michael Conte, MD	University of California San Francisco, Division of Vascular and Endovascular Surgery—Professor and Chief; UCSF Heart and Vascular Center—Co-Director; UCSF Center for Limb Preservation—Co-Director	AHA	<ul style="list-style-type: none"> • Cook Medical • Medtronic 	None	None	• Bard (DSMB)	<ul style="list-style-type: none"> • Chief, Vascular Surgery (Honoraria)†‡ • Co-Director, Heart and Vascular Center (Salary)‡ 	None
Sean R. Dariushnia, MD	Emory University School of Medicine, Department of Radiology and Imaging Sciences, Division of Interventional Radiology and Image-Guided Medicine—Assistant Professor	SIR	None	None	None	None	None	None
Alain T. Drooz, MD	INOVA Fairfax Hospital—Staff Physician	SVM	<ul style="list-style-type: none"> • Philips/ PercuNav†‡ • Possis Medical/ Boston Scientific†‡ 	• Bayer/Onyx Pharmaceutical	None	<ul style="list-style-type: none"> • Bard (DSMB) • Cordis 	• SIRTEX Medical†	None
Joseph P. Hughes, RVT, RVS	NAVIX Diagnostix—Director of Business Development; Society for Vascular Ultrasound—President	SVU	None	None	None	None	None	None

2018 Appropriate Use Criteria for Peripheral Artery Intervention
CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
J. Kevin McGraw, MD	Riverside Methodist Hospital, Interventional Radiology—Section Head; Riverside Radiology and Interventional Associates	SIR	• Stryker	None	None	None	None	None
George H. Meier, MD, RVT	University of Cincinnati College of Medicine, Vascular Surgery—Professor, Chief, and Program Director	SVU	None	None	None	None	None	None
Jeffrey W. Olin, D.O.	Icahn School of Medicine at Mount Sinai, Cardiovascular Institute and Center for Cardiovascular Health, Vascular Medicine and Vascular Diagnostic Laboratory—Director and Professor of Medicine (Cardiology)	ACC	• Fibromuscular Dysplasia Society of America† • Janssen Pharmaceuticals, Inc.	None	• Northwind†	• Astra Zeneca†	• Astra Zeneca	None
Gregory Piazza, MD	Brigham and Women's Hospital, and Harvard Medical School—Assistant Professor of Medicine	ACC	• Agile • BCRI† • BIO2 • Exithera • Optum	None	None	• BMS† • Daiichi • EKOS† • Janssen Pharmaceuticals, Inc.† • NHLBI • Thrombosis Research Institute	None	None

2018 Appropriate Use Criteria for Peripheral Artery Intervention
CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Eva M. Rzucidlo, MD	McLeod Vascular Associates of South Carolina—Vascular Surgeon; Dartmouth Medical School—Associate Professor of Surgery	SVS	None	None	None	None	None	None
Drew C. Schemmer, MD	Royal Victoria Regional Health Center, Diagnostic Imaging, Vascular and Interventional Radiology Department—Vascular Radiologist	SIR	None	None	None	None	None	None
Marc Schermerhorn, MD	Beth Israel Deaconess Medical Center, Vascular and Endovascular Surgery Department—Chief; Harvard Medical School—Professor of Surgery	SVS	<ul style="list-style-type: none"> • Abbott Laboratories† • Cook • Philips 	None	None	<ul style="list-style-type: none"> • Endologix (DSMB)† • Medtronic Vascular – ENGAGE PAS (PI)‡ 	<ul style="list-style-type: none"> • Bolton Medical Inc* • Boston Scientific Inc* • Cook Medical* • Medtronic Vascular* • National Institutes of Health* • Philips Healthcare* • Silk Road Medical* • University of Vermont* • W.L. Gore & Associates* 	None
Mehdi Shishehbor, MD	Cleveland Clinic, Endovascular Services—Director	ACC	<ul style="list-style-type: none"> • Abbott‡ • BioClinica‡ • Boston Scientific‡ • Medtronic‡ • Philips‡ • Shockwave Medical‡ • Spectranetics‡ • Terumo‡ • Volcano‡ 	None	None	None	<ul style="list-style-type: none"> • Astra Zeneca* • National Institutes of Health* • Volcano/ Philips* 	None

2018 Appropriate Use Criteria for Peripheral Artery Intervention

CONFIDENTIAL AND EMBARGOED

Participant	Employment	Representing	Consultant	Speaker's Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
David P. Slovut, MD, PhD, MHA	Network Performance Group—Director of Cardiovascular Quality; Montefiore Medical Center, Cardiology, Patient Safety and Quality—Vice Chief; TAVR—Co-Director; Medicine and Cardiovascular and Thoracic Surgery—Professor	SVM	None	None	None	None	None	None
Eric H. Yang, MD	Mayo Clinic of Arizona, Cardiac Catheterization Laboratory—Director	AHA	None	None	None	None	None	None
Appropriate Use Criteria Task Force								
RWI and disclosure statements for members of the ACC Task Force on Appropriate Use Criteria can be found here: http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces								

This table represents *comprehensive* relationships of participants with industry and other entities that were reported at the time this document was under development. The table does not necessarily reflect relationships with industry at the time of publication.

A person is deemed to have a *significant* interest in a business if the interest represents ownership of $\geq 5\%$ of the voting stock or share of the business entity, or ownership of $\geq \$5,000$ of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. Relationships in this table with no symbol are considered *modest* (less than significant under the preceding definition). Relationships that exist with *no financial benefit* are also included for the purpose of transparency. Please refer to <http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy> for definitions of disclosure categories or additional information about the ACC Disclosure Policy for Writing Committees.

- * Clinical Trial Enroller.
- † Significant relationship.
- ‡ No financial benefit.

ACC = American College of Cardiology; ACR = American College of Radiology; AHA = American Heart Association; AUC = Appropriate Use Criteria; Co-PI = Co-Principal Investigator; DSMB = Data Safety Monitoring Board; PI = Principal Investigator; SCAI = Society for Cardiovascular Angiography and Interventions; SCVS = Society for Clinical Vascular Surgery; SIR = Society of Interventional Radiology; SVM = Society for Vascular Medicine; SVS = Society for Vascular Surgery; SVU = Society for Vascular Ultrasound.